Emerging Markets Earnings Roundup: Roche (Part 7)
This article was originally published in PharmAsia News
Executive Summary
Roche’s international growth in pharmaceuticals was a modest 2% in the second quarter, a likely reason for a generally subdued earnings call. But the tone was upbeat on the second half with a few clues offered on M&A strategy.
You may also be interested in...
Roche Not Ruling Out Creative Deals For ‘Tail End’ Brands
A better value proposition and more in-tune marketing ideas would drive a more creative risk-sharing or asset swap-like arrangement for the oncology specialist’s more mature brands, says Roche CEO Severin Schwan.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.